Product logins

Find logins to all Clarivate products below.


Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)

AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the first-line mainstay therapy, but in topical-refractory patients, symptoms are managed with systemic therapies. The launch of targeted AD therapies such as biologics from Sanofi / Regeneron (Dupixent [dupilumab]) and LEO Pharma (Adbry [(tralokinumab]), two oral JAK inhibitors (AbbVie’s Rinvoq [upadacitinib] and Pfizer’s Cibinqo [abrocitinib]), one topical JAK inhibitor (Incyte’s Opzelura [ruxolitinib]), and a topical aryl hydrocarbon receptor agonist (Dermavant’s Vtama [tapinarof 1% cream]) have greatly expanded the treatment options for adult AD patients across the severity spectrum. This claims data analysis explores usage patterns of these newer therapies relative to historical mainstays of treatment and provides valuable insight into evolving U.S. drug-treatment trends in AD.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult AD patients?
  • How have Cibinqo, Rinvoq, and Vtama been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of adult AD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of adult AD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Geography: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Adbry, Cibinqo, Dupixent, Opzelura, Rinvoq, Vtama, oral immunosuppressants, corticosteroids (topical and oral), topical calcineurin inhibitors

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula leading to vision impairment and…